Genmab regains rights to HuMax-CD4
Genmab A/S announced it has regained all rights to the HuMax-CD4® (zanolimumab) antibody from Merck Serono S.A. Genmab plans to continue moving development of HuMax-CD4 forward in the existing non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma clinical programs and expand development into earlier stage patients in combination with PUVA as well as other combinations with approved therapies for CTCL.
In addition, Genmab is making plans to develop a UniBody(TM) targeting the CD4 receptor. HuMax-CD4 binds the CD4 molecule with very high affinity and effectively blocked and neutralized infection of a broad panel of HIV-1 viruses isolated from infected individuals. Laboratory studies in an immunodeficient (SCID) mouse model, where animals were reconstituted with human blood cells, showed HuMax-CD4 to effectively block HIV-1 replication and reduce depletion of CD4+ T-cells by the virus. A UniBody targeting CD4 represents a promising drug candidate that may prevent or slow HIV-1 infection and AIDS and spare T-cells.
Worldwide rights to HuMax-CD4 were previously licensed to Merck Serono S.A. in August 2005. Regaining rights to HuMax-CD4 will not influence Genmab's financial guidance for 2007.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.